ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,351Medicare Part D Prescriptions Filled, Including Refills

Rank: 167 out of 1006

$825K Total Retail Price of All Prescriptions

Rank: 72 out of 1006

444 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
53% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 444 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 444 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 7,232 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

34% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$99 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
ATORVASTATIN CALCIUM 304 294 1 5
AMLODIPINE BESYLATE 287 274 2 4
OMEPRAZOLE 283 235 3 9
METOPROLOL TARTRATE 232 211 4 7
FUROSEMIDE 219 205 5 6
TAMSULOSIN HCL 192 175 6 23
SIMVASTATIN 186 157 7 1
LEVOTHYROXINE SODIUM 177 143 8 2
HYDROCODONE-ACETAMINOPHEN 136 115 S3 9 25
METOPROLOL SUCCINATE 135 117 10 12
CITALOPRAM HBR 134 110 11 24
NEXIUM 131 105 12 28
GLIMEPIRIDE 130 115 13 50
TRIAMTERENE-HCTZ 120 93 14 58
LIPITOR 119 103 15 47
METFORMIN HCL 115 109 16 10
LISINOPRIL 103 94 17 3
WARFARIN SODIUM 102 102 18 8
AMLODIPINE BESYLATE-BENAZEPRIL 101 94 19 77
DONEPEZIL HCL 101 97 19 17
ZOLPIDEM TARTRATE 86 66 21 14
VENLAFAXINE HCL ER 83 41 22 105
AZITHROMYCIN 82 70 23 39
LOSARTAN POTASSIUM 76 70 24 22
DIOVAN HCT 74 62 25 60
JANUMET 74 58 25 151
CEFUROXIME 72 59 27 170
DIOVAN 72 68 27 16
ALLOPURINOL 71 71 29 31
ESCITALOPRAM OXALATE 69 62 30 27
NAMENDA 68 68 31 34
LOSARTAN-HYDROCHLOROTHIAZIDE 64 60 32 81
PANTOPRAZOLE SODIUM 63 57 33 32
PLAVIX 61 55 34 61
JANUVIA 59 50 35 49
GLYBURIDE 58 58 R 36 65
VERAPAMIL ER 58 58 36 116
AMOXICILLIN 55 45 38 156
ADVAIR DISKUS 55 55 38 37
MECLIZINE HCL 55 45 38 137
TRAMADOL HCL 54 42 41 35
BENICAR HCT 54 51 41 120
LEVETIRACETAM 54 17 41 72
PRAVASTATIN SODIUM 53 53 44 15
ATENOLOL 51 41 45 13
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.